Clinical Trial Update: Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety and efficacy of adding AMD3100 to a G-CSF mobilization regimen in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Mozobil (Plerixafor) (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma, Non Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED